• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SeaSpine® Announces New Senior Leadership Team Appointments

    5/3/22 4:04:00 PM ET
    $SPNE
    Medical Specialities
    Health Care
    Get the next $SPNE alert in real time by email

    CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team.

    Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influential leader in enabling and financing SeaSpine's growth and has assumed increasing operational responsibilities during his tenure. In his expanded role, John will drive operational excellence and continuous improvement initiatives across product development, marketing, quality, regulatory, and supply chain operations for the global spinal implants portfolio. He will be responsible for implementing an operating strategy that drives gross margin and operating leverage while generating revenue growth well above market.

    "We believe that SeaSpine has never been in a better position to capitalize on tremendous growth opportunities in the current spine market," stated Keith Valentine, President and CEO. "With John's expanded leadership role, I am confident that together we can further scale the business and facilitate deeper cross-functional collaboration that will drive operating efficiencies and better predictability and accountability for improved results that match our accelerated revenue growth. John's new focus will also enable me to engage in a stronger customer-facing mission with a greater emphasis on our commercial efforts."

    Ms. Winkler will be responsible for architecting SeaSpine's human resources strategy, including talent acquisition, talent management, diversity and inclusion, compensation and benefits, and employee engagement. In collaboration with senior leadership, Hollis will continue to build a culture that attracts, retains and develops the talent needed to provide the best in spine patient care. Hollis has over 20 years of experience leading human resources strategy, with a focus on business and culture transformation, mergers and acquisitions, and organizational effectiveness. Prior to joining SeaSpine, she served as Vice President, Human Resources at GenMark Diagnostics and, before that, Vice President, Human Resources at Thermo Fisher Scientific.

    "Hollis has experience as a transformational Human Resources leader with numerous organizations," said Mr. Valentine. "She appreciates how the pandemic has created new challenges and changed the workplace environment, and I look forward to seeing her leverage her extensive experience as we navigate a very challenging labor market and seek to further strengthen our employee engagement and retention to enable our growth plans."

    About SeaSpine

    SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine's complete procedural solutions feature its market-leading FLASH™ Navigation, a system designed to improve accuracy of screw placement and provide a cost-effective, rapid, radiation-free solution to surgical navigation, and a comprehensive portfolio of spinal implants and orthobiologics to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures on the lumbar, thoracic and cervical spine. With product development expertise in advanced optics, software, orthobiologic sciences and spinal implants, SeaSpine can offer its surgeon customers a complete solution to meet their patients' evolving clinical needs. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.

    Forward-Looking Statements

    SeaSpine cautions you that statements in this press release that are not a description of historical facts are forward-looking statements based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the belief that SeaSpine is better positioned than ever to capitalize on tremendous growth opportunities in the current spine market; and the confidence that, with Mr. Bostjancic's expanded leadership role, the Company can further scale its business and facilitate clearer cross-functional collaboration that will drive operating efficiencies and better predictability and accountability for improved operating results. Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward looking statements are risks and uncertainties that include, but are not limited to: the extent of the impact of the COVID-19 pandemic on the Company's business and the economy; reductions in surgical volumes, including the duration of any elective surgery deferrals; the impact of staffing shortages; surgeons' willingness to adopt the Company's newly launched products; the risk of supply shortages and associated disruption to product sales; general economic and business conditions in the markets in which the Company does business, both in the U.S. and abroad; and other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

    You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

    Investor Relations Contact

    Leigh Salvo

    (415) 937-5402

    [email protected]



    Primary Logo

    Get the next $SPNE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SPNE

    DatePrice TargetRatingAnalyst
    11/2/2022$12.00 → $6.75Buy → Hold
    Truist
    4/22/2022$27.00 → $21.00Overweight
    Cantor Fitzgerald
    4/13/2022$20.00Buy
    Truist
    12/21/2021$25.00 → $20.00Buy
    Truist Securities
    10/28/2021$100.00Buy
    Loop Capital
    More analyst ratings

    $SPNE
    Financials

    Live finance-specific insights

    See more
    • SeaSpine to Report Third Quarter 2022 Financial Results on November 1, 2022

      CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des

      10/24/22 7:00:00 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

      Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin

      10/11/22 6:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • SeaSpine Reports 19% Revenue Growth and Record Quarterly Revenue for Second Quarter 2022 and Raises Full Year 2022 Revenue Guidance

      CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today second quarter financial results for the three-months ended June 30, 2022. Summary Second Quarter 2022 Financial Results and Recent Highlights Total revenue of $56.3 million, an increase of 19% year-over-yearU.S. revenue of $49.5 million, an increase of 16% year-over-year U.S. spinal implants and enabling technologies revenue of $25.0 million, an increase of 17% year-over-yearU.S. orthobiologics revenue of $24.5 million, an increase of 16% year-over-year International reve

      8/2/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:21:07 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:51 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:35 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System

      CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru

      12/27/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $SPNE
    SEC Filings

    See more
    • SEC Form CT ORDER filed by SeaSpine Holdings Corporation

      CT ORDER - SeaSpine Holdings Corp (0001637761) (Filer)

      4/3/23 8:19:25 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by SeaSpine Holdings Corporation

      15-12G - SeaSpine Holdings Corp (0001637761) (Filer)

      1/17/23 4:31:53 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by SeaSpine Holdings Corporation

      EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)

      1/12/23 12:15:22 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      1/31/23 1:58:01 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/14/22 11:45:59 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/3/22 4:41:28 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SeaSpine downgraded by Truist with a new price target

      Truist downgraded SeaSpine from Buy to Hold and set a new price target of $6.75 from $12.00 previously

      11/2/22 6:34:40 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Cantor Fitzgerald resumed coverage on SeaSpine with a new price target

      Cantor Fitzgerald resumed coverage of SeaSpine with a rating of Overweight and set a new price target of $21.00 from $27.00 previously

      4/22/22 9:10:58 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Truist resumed coverage on SeaSpine with a new price target

      Truist resumed coverage of SeaSpine with a rating of Buy and set a new price target of $20.00

      4/13/22 7:17:39 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Leadership Updates

    Live Leadership Updates

    See more
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team. Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influentia

      5/3/22 4:04:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants. With his promotion, Mr. Bannigan joins the SeaSpine Senior Leadership Team. Dr. Vizesi joined SeaSpine in 2015 as Director, Research and Development, Orthobiologics. He quickly elevated the approach and defined the vision for delivering best-in-class orthobiologics procedural solutions. Under Dr. Vizesi's leadership, the team deepened

      3/7/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

      CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent. Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she i

      12/14/21 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care